Countries China
Mölnlycke Establishes First Wound Care Manufacturing Site in China to Strengthen Local Production and Supply Chain Resilience
Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound car...
November 06, 2025 | News
Ailux and Eli Lilly Forge $345 Million AI-Driven Collaboration to Accelerate Bispecific Antibody Discovery
Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a stra...
November 06, 2025 | News
BioDlink and Lepu Biopharma Achieve China Approval for First-in-Class EGFR-Targeted ADC in Nasopharyngeal Carcinoma
BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma T...
November 06, 2025 | News
LakeShore Biopharma to Go Private in US$37 Million Merger with Oceanpine Group
LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discove...
November 05, 2025 | News
Sanyou Biopharmaceuticals and Shanghai ZJ Bio-Tech Forge Strategic Partnership to Accelerate Automated Development of Innovative Biologics
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referre...
November 04, 2025 | News
Hasten Biopharmaceutical Completes 70 Marketing Authorization Transfers and Builds End-to-End Commercial Network Across Asia-Pacific
Hasten Biopharmaceutical Co., Ltd. ("Hasten") announced that while completing 70 Marketing Authorization Transfers (MAT) for its Asia-Pacific pro...
November 05, 2025 | News
Akeso Secures Fourth Breakthrough Therapy Designation for Ivonescimab in Combination Therapy for Triple-Negative Breast Cancer
Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for fi...
November 04, 2025 | News
4D Molecular Therapeutics and Otsuka Form $471 Million Partnership to Advance 4D-150 Gene Therapy Across Asia-Pacific
4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for dev...
November 04, 2025 | News
4D Molecular Therapeutics and Otsuka Form $471 Million Partnership to Advance 4D-150 Gene Therapy Across Asia-Pacific
4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for dev...
November 04, 2025 | News
NovaBridge Subsidiary Visara Assigns Exclusive License for VIS-101 to Everest Medicines to Advance Treatment for Wet AMD Across Asia
NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet...
November 03, 2025 | News
JW Therapeutics Expands Strategic Collaboration with Regeneron to Advance TCR-T Cell Therapy and Platform Innovation
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunother...
November 03, 2025 | News
Shanghai Zhimeng Biopharma Begins Phase 2/3 Trial of Next-Generation Potassium Channel Opener for ALS
Previously (in July 2025), CB03-154 received approval from the China Center for Drug Evaluation (CDE) to conduct the ALS phase 2/3 adaptive clin...
November 03, 2025 | News
Everest Medicines Expands into Ophthalmology with Exclusive License for VIS-101 from Visara, a NovaBridge Subsidiary
Everest Medicines announced that it has acquired an exclusive license with Visara, Inc. (“Visara”), a subsidiary of NovaBridge Biosciences (for...
October 31, 2025 | News
Starna Therapeutics Secures Over RMB 300 Million in Series B Financing to Accelerate in vivo CAR-T Innovation
Starna Therapeutics, a pioneering biotechnology company developing next-generation RNA and in vivo CAR-T therapies, today announced the successful closing ...
October 30, 2025 | News
Most Read
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
